Article
BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2017
Lips Esther H, Debipersad Rashmie D, Scheerman Caroline E, Mulder Lennart, Sonke Gabe S, van der Kolk Lizet E, Wesseling Jelle, Hogervorst Frans B L, Nederlof Petra M
Abstract excerpt
Purpose: As estrogen receptor-positive (ER+) breast cancer in BRCA1 mutation carriers arises at an older age with less aggressive tumor characteristics than ER-negative (ER-) BRCA1-mutated breast cancer, it has been suggested that these tumors are "sporadic" and not BRCA1 driven. With the introduction of targeted treatments specific for tumors with a nonfunctioning BRCA1 or BRCA2 gene, the question whether the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.